GP practice owners choose between three buyer types: internal succession (2.5 to 3.5 times EBITDA), GP group or privately owned medical group (3 to 4 times), or ASX-listed or private-equity-backed corporate (4 to 6 times). Higher multiples carry earnouts, GP retention clawbacks and cultural change. The choice sets transaction structure, timeline and legacy trade-offs.
Practice owners preparing for sale face a key decision that determines transaction structure, timeline and outcomes. Do you prioritise legacy and community continuity, staff retention and culture preservation, or pure financial optimisation and capital realisation?
This decision shapes which buyer types you target, how you structure the transition, and what trade-offs you accept between sale price, GP retention and post-sale involvement.
Buyer type options
1. Internal succession: existing GPs buy in
Best for: owners prioritising legacy, community continuity and phased exit over maximum capital realisation.
Advantages:
- Preservation of cultural continuity and community relationships
- Existing GPs understand practice operations and patient base
- Minimal upset to staff and patients
- Can structure phased transition with retained involvement
Disadvantages:
- GPs may lack capital for a full buyout (requires vendor finance or gradual payments)
- Valuation is often conservative (sellers may have a kinder disposition towards a known buyer and buyers better understand practice weaknesses)
- Protracted timeline for capital realisation
- Succession planning becomes more complex when multiple GPs are involved
2. GP group or privately-owned medical group
Best for: owners wanting a balance between legacy preservation and sale price, comfortable with gradual integration.
Advantages:
- Buyer understands GP practice operations and sector dynamics
- More likely to retain practice culture and branding
- May retain existing GPs through competitive employment terms
- Operational autonomy is often preserved (group provides back-office support)
Disadvantages:
- Valuation is typically conservative (operational buyers focused on EBITDA multiples)
- May require owner retained involvement for the transition period
- The group may, over time, impose standardised systems or protocols
3. Corporate buyer (ASX-listed or private equity-backed)
Best for: owners prioritising maximum capital realisation and clean exit over legacy and culture preservation.
Advantages:
- Highest valuation multiples (corporate buyers pay for platform growth potential)
- Cleanest exit (full capital realisation, minimal vendor finance)
- Shortest transaction timeline (corporate buyers have capital and systems ready)
- Professional management reduces owner involvement post-sale
Disadvantages:
- Cultural change is likely (corporate systems, branding, protocols imposed)
- GP retention risk is higher (corporates often restructure employment terms)
- Community perception may shift (patients see corporate takeover)
- Limited post-sale influence over practice direction
Decision framework
If legacy and community continuity are primary:
- Favour internal succession or GP group buyers
- Accept lower valuation multiples for cultural alignment
- Structure phased transition with retained involvement
- Prioritise GP and staff retention terms in the sale agreement
If financial optimisation is primary:
- Target corporate buyers willing to pay premium multiples
- Accept cultural change and operational integration
- Structure a clean exit with minimal post-sale involvement
- Focus negotiation on price and capital realisation timeline
If there is a balance between legacy and price:
- Target privately-owned GP groups with growth capital
- Negotiate GP retention commitments and cultural integration limits
- Consider a staged exit with an earn-out tied to performance
- Maintain some post-sale advisory role during transition
Practical consequences
Your buyer selection strategy affects:
Sale preparation priorities:
Corporate buyers scrutinise EBITDA normalisation, operational KPIs and systems documentation more intensively than internal succession buyers who already know the practice.
GP retention planning:
If legacy matters, you need documented GP retention commitments before sale. If financial optimisation matters, you negotiate GP handover as buyer responsibility post-sale.
Transaction structure:
Internal succession requires vendor finance and staged payments. Corporate buyers offer clean exits. GP groups often want the owner's involvement in transition.
Timeline:
Corporate buyers move fastest (3-6 months from due diligence to settlement). Internal succession takes the longest (12-24 months for capital arrangement and staged transition). GP groups sit in between.
Valuation expectations: Corporate buyers pay 4-6x EBITDA for quality practices. GP groups pay 3-4x EBITDA. Internal succession often 2.5-3.5x EBITDA due to capital constraints and conservative risk assessment.
Corporate buyers (often around 4-6x EBITDA) typically offer the highest stated multiples, but that figure rarely represents a clean upfront payment. Most corporate deals include an earnout component tied to post-sale billing continuity and GP retention over a defined period, typically one to five years depending on the buyer and the practice's GP concentration risk. If key GPs leave or billings drop below agreed targets during the earnout period, the effective price paid falls. The multiple quoted at the start of negotiations may be undermined.
GP group buyers (often around 3-4x EBITDA) generally offer lower multiples than corporates but may structure deals with fewer contingencies. Earnout components are still common, particularly where the selling owner's clinical billings represent a material share of practice revenue. Some GP groups build retention incentives into the service agreement terms offered to existing tenant GPs, such as improved fee splits or reduced notice periods, rather than making GP retention a condition of the purchase price itself.
Internal succession (often around 2.5-3.5x EBITDA) sits lowest on stated price, partly because incoming GP buyers have less capital and partly because they already know the practice's weaknesses, while owners have a positive disposition towards the purchasers. These deals are more likely to involve vendor finance, staged payments over two to five years and informal retention arrangements rather than formal earnouts. The trade-off is lower transaction risk: the buyer is already embedded in the practice and less likely to trigger GP departures or patient attrition.
In all three cases, the seller should assess the deal on total expected proceeds after all conditions are met, not on the stated multiple alone. A higher multiple with aggressive earnout conditions and GP retention clawbacks may deliver less than a lower multiple with cleaner terms.
When to decide
The buyer selection strategy should inform sale preparation, not be decided during the sale process.
If you are targeting corporate buyers, invest in EBITDA normalisation, KPI implementation and operational documentation. If targeting internal succession, focus on GP retention planning and partnership structuring. If targeting GP groups, balance operational documentation with cultural preservation planning.
Practice owners who start sale preparation without clarity on buyer priorities waste time on documentation that does not serve their actual goals.